Evidence map›Paper›PMID 32231024›Full record

ArticleMolecules (Basel, Switzerland)2020

Genetic Polymorphism of GSTP-1 Affects Cyclophosphamide Treatment of Autoimmune Diseases.

Péter Hajdinák, Melinda Szabó, Emese Kiss, Lili Veress, Lívius Wunderlich, András Szarka

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Péter HajdinákDepartment of Applied Biotechnology and Food Science, Laboratory of Biochemistry and Molecular Biology, Budapest University of Technology and Economics, Szent Gellért tér 4., Budapest 1111, Hungary.ORCID 0000-0002-7705-2074
Melinda SzabóNational Institute of Rheumatology and Physiotherapy, Clinical Immunology Adult and Pediatric Rheumatology, Frankel Leó u. 25-29., Budapest 1023, Hungary.
Emese KissNational Institute of Rheumatology and Physiotherapy, Clinical Immunology Adult and Pediatric Rheumatology, Frankel Leó u. 25-29., Budapest 1023, Hungary.
Lili VeressNational Institute of Rheumatology and Physiotherapy, Clinical Immunology Adult and Pediatric Rheumatology, Frankel Leó u. 25-29., Budapest 1023, Hungary.
Lívius WunderlichDepartment of Applied Biotechnology and Food Science, Laboratory of Biochemistry and Molecular Biology, Budapest University of Technology and Economics, Szent Gellért tér 4., Budapest 1111, Hungary.
András SzarkaDepartment of Applied Biotechnology and Food Science, Laboratory of Biochemistry and Molecular Biology, Budapest University of Technology and Economics, Szent Gellért tér 4., Budapest 1111, Hungary.ORCID 0000-0001-6594-254X
National Institute of Oncology · HUBudapest University of Technology and Economics · HUSemmelweis University · HU

Funding

Innovációs és Technológiai Minisztérium BME FIKP BIONemzeti Kutatási Fejlesztési és Innovációs Hivatal K 123752, 129593, 2018-1.2.1-NKP-2018-00005
6 · The paper itself

Abstract

Cyclophosphamide is one of the most potent and reliable anti-cancer and immunosuppressive drugs. In our study, 33 individuals with different autoimmune diseases were treated with cyclophosphamide according to standard protocols. The responses to the treatments were determined by measuring the alteration of several typical parameters characterizing the given autoimmune diseases over time. We concluded that about 45% of the patients responded to the treatment. Patients were genotyped for polymorphisms of the CYP3A4, CYP2B6, GSTM1, GSTT1, and GSTP1 genes and disease remission cases were compared to the individual polymorphic genotypes. It was found that the GSTP1 I105V allelic variation significantly associated with the cyclophosphamide treatment-dependent disease-remissions. At the same time the GSH content of the erythrocytes in the patients with I105V allelic variation did not change. It appears that the individuals carrying the Ile105Val SNP in at least one copy had a significantly higher response rate to the treatment. Since this variant of GSTP1 can be characterized by lower conjugation capacity that results in an elongated and higher therapeutic dose of cyclophosphamide, our data suggest that the decreased activity of this variant of GSTP1 can be in the background of the more effective disease treatment.

Indexed as

Pharmacogenomic VariantsPolymorphism, GeneticAdultAgedAged, 80 and overAllelesAutoimmune DiseasesBiomarkersCyclophosphamideCytochrome P-450 Enzyme SystemFemaleGene FrequencyGlutathioneGlutathione S-Transferase piHumansImmunosuppressive AgentsBiomarkersCyclophosphamideCytochrome P-450 Enzyme SystemGlutathioneGlutathione S-Transferase piImmunosuppressive Agentsautoimmune diseasescyclophosphamideglutathioneglutathione-S-transferasepolymorphism

Identifiers

PMID32231024
PMCPMC7180851
OpenAlexW3014018439

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.